$ARDX stock is up by 55% since it lobbied Congress in early Feb on Medicare

On February 1st, after Ardelyx spent $340k lobbying Congress on issues related to Medicare ESRD benefits & chronic kidney disease management, our Lobbying Spending Growth Strategy went long on $ARDX. The stock has soared nearly 55% since.

6:20 PM · Mar 30, 2023

Read 1 reply

$ARDX stock is up by 55% since it lobbied Congress in early Feb on Medicare

United Auto Workers Chief Criticizes Trump’s Ties to Musk Amid Harris Campaign

Boozman Releases New Batch of Trades Amidst Possible Ban

Lilly and Novo Nordisk Compete for Weight-Loss Market Dominance

Pelosi's Strategic Moves in MSFT & NVDA Capture Market Attention

AMD Boosts 2024 AI Chip Forecast by $500 Million

Rep. Virginia Foxx adds $ASC and $EFC-D to her portfolio in July

Rep. Lloyd Doggett reinvests in Coca-Cola, stock surges over 7%

Rep. Lee adjusts Apple portfolio, selling calls & buying puts

Crypto market crashes but some top investment managers are still holding on

Voters poll reveals more confidence in Trump's financial impact than Harris